{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:20:57Z","timestamp":1777929657509,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Anhand eines Krankengutes von 223 Patienten mit Kardiakarzinom werden die chirurgische Problematik und die Ergebnisse nach palliati-ven, radikalen und erweiterten Resektionen besprochen. Im dr\u00fcsen-freien Fr\u00fchstadium (I) konnte in 72 % der radikal operierten Patienten eine 5- bis 10-Jahresheilung erreicht werden; bezogen auf alle beob-achteten Patienten liegt die Leistungszahl allerdings nur bei 10 % bei 5 Jahren und 8 % bei 10 Jahren. Dies ist dadurch bedingt, da\u00df uns nur wenig mehr als 10 % unserer Kranken im dr\u00fcsenfreien Stadium I zuge-wiesen werden. Die Forderung f\u00fcr ein \u00dcberwachungsprogramm f\u00fcr klar zu definierende Risikogruppen mu\u00df erhoben werden, und die M\u00f6glichkeiten einer speziellen postoperativen Zusatztherapie sollten voll genutzt werden.<\/jats:p>","DOI":"10.1159\/000213951","type":"journal-article","created":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T11:28:57Z","timestamp":1239881337000},"page":"197-200","source":"Crossref","is-referenced-by-count":4,"title":["Zur Prognose des Kardiakarzinoms"],"prefix":"10.1159","author":[{"given":"H.","family":"Denck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pridun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,15]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/213951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000213951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:48:16Z","timestamp":1777679296000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000213951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000213951","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}